Biogen (BIIB) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 EPS Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.78 +1.13%
Financial Fact:
Net income attributable to Biogen Idec Inc.: 1.03B
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Net income attributable to Biogen Idec Inc.: 1.03B
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q2 EPS of $3.60, $0.43 better than the analyst estimate of $3.17. Revenue for the quarter came in at $2.74 billion versus the consensus estimate of $2.43 billion.
GUIDANCE:
Biogen sees FY2026 EPS of $12.00-$13.00, versus the consensus of $12.72.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- Kimbell Royalty closes $221.2M mineral rights acquisition
- Is the global equity rally broadening? UBS weighs in
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
